Research programme: eIF4E targeted therapeutics - Ribometrix
Alternative Names: Program-1; RBX-eIF4EiLatest Information Update: 09 Apr 2024
At a glance
- Originator Ribometrix
- Class Antineoplastics; RNA; Small molecules
- Mechanism of Action Eukaryotic initiation factor 4E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Apr 2024 Ribometrix plans to file an IND application in Solid tumours in 2025
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in solid tumours presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 08 Dec 2023 Pharmacodynamics data from a preclinical trial in Solid tumors released by Ribometrix